In the 1980s the German mycologist Jochen Gartz published a series of provocative scientific papers that detailed a process for introducing synthetic tryptamines into the substrate of Psilocybe cubensis leading to the growth of mushrooms with an unprecedented concentration of psilocin. This presentation represents the results of the first effort to reproduce Gartz's research with quantitative chemical analysis.
Hamilton Morris
Paul Stamets and Pamela Kryskow discuss the diverse history and potential of psilocybin mushrooms, highlighting their cultural and medical significance in human evolution and mental health treatment. Kryskow emphasizes the
Pam Kryskow, Paul Stamets
Psilocybin service center facilitator discusses ceremonies and natural medicines in Colorado and Oregon's new state frameworks for participation in natural medicine practices.
William Wildcat Coakee, Sean McAllister, Dave Kopilak
Speaker discusses underlying assumptions of psychedelic therapy and therapist's role, emphasizing presence in facilitating healing. Draws from personal experiences with MDMA, psilocybin, and ketamine research volunteers.
Norma Stevens
Psilocybin therapy tested for safety, feasibility, and efficacy in cancer patients with major depressive disorder, using group treatment in a cancer center setting. Clinical trial details: NCT04593563.
Betsy Jenkins
Study investigates psilocybin's effects on depression and burnout in healthcare clinicians post-COVID frontline work with pre- and post-dose psychotherapy. Trial registration: NCT05163496.
Anthony L Back
Clinicians and researchers discuss integrating psilocybin-assisted therapy into serious illness care models, presenting preliminary findings from a pilot study in hospice care for patients with terminal illness.
Yvan Beaussant, Roxanne Sholevar, Lisa Summer, Robin McKenna
Psilocybin trial for advanced cancer patients will compare effects of 25mg dose to 1mg placebo on anxiety, depression, and existential distress, using psychotherapy to assess efficacy and psychological mechanisms.
Overview of a multicenter trial compares psilocybin therapy to active control for demoralization in end-of-life adults. Trial focuses on treating depression, anxiety, and improving quality of life, spiritual well-being, and
Jessi Humphreys
Dr. Smith and Dr. Jones explore the latest research on psychedelic therapy and its potential impact on mental health during the PS2023 conference.
Stacy Fischer, Anthony “Tony” Bossis, Charles S Grob, Manish Agrawal, Shoshana Ungerleider
© 1986 – 2025 Multidisciplinary Association for Psychedelic Studies. All Rights Reserved.
3141 Stevens Creek Blvd #40563, San Jose, CA 95117.
Mailing: MAPS P.O. Box 103004 Pasadena, CA 91189-3004.